(Press-News.org) Present-day lithium batteries are efficient but involve a range of resource and environmental problems. Using materials from alfalfa (lucerne seed) and pine resin and a clever recycling strategy, Uppsala researchers have now come up with a highly interesting alternative. Their study will be presented soon in the scientific journal ChemSusChem.
'We think our discovery can open several doors to more environment-friendly, energy-efficient solutions for the batteries of the future,' says Daniel Brandell, Associate Professor at the Department of Chemistry, Uppsala University, one of the researchers behind the idea.
Lithium-ion batteries are, thanks to their high energy content, highly promising for various products — not least, electric vehicles or large-scale energy storage in the electricity grid — in the future energy system. But present-day lithium batteries entail a number of resource-related and environmental problems. For a start, the world's commercially extractable lithium resources are limited and whether they can meet future needs is unclear. Moreover, it is very difficult to recover lithium from the inorganic materials used to make modern batteries. What is more, lithium batteries contain other, even rarer materials that are hard to replace and require large energy inputs and toxic chemicals for the recovery process.
In the latest study, researchers at Uppsala University's Ångström Laboratory have developed a whole new battery concept. The battery is based on recovery and renewable biological material with an energy content corresponding to that of current lithium-ion batteries. Components of the battery are made of renewable organic biomaterials from alfalfa and pine resin, and can be recycled with a low energy input and non-hazardous chemicals, such as ethanol and water.
Although present-day batteries contain non-renewable inorganic materials, this is not the first time batteries composed of renewable materials have been presented. But the recycling and recovery strategy is a wholly new concept. Constructing a new battery from a spent one is also feasible. In other words, a straightforward process enables it to be reused.
The scientists have shown that the lithium extracted from a spent battery can be used for a new battery: all that needs to be added is more biomaterial. Their battery proved capable of delivering as much as 99% of the energy output from the first. With future modifications, this figure can very probably become even higher, say the researchers.
Daniel Brandell adds: 'The use of organic materials from renewable sources makes it possible to solve several of the problems that would arise from a huge rise in the use of lithium batteries. But above all, it's a major step forward that, to a high degree and in a simple, environment-friendly way, the lithium from these batteries can be recovered. These solutions are also potentially very cost-effective.'
INFORMATION:
The research team also includes Professor Kristina Edström, who heads battery research at Uppsala University, and researcher Stéven Renault. (Photographer: Anders Lund).
Read the article that has been accepted (NB not the final version) at: http://onlinelibrary.wiley.com/doi/10.1002/cssc.201402440/abstract.
Reference: Stéven Renault, Daniel Brandell, Kristina Edström, Environmentally-friendly lithium recycling from a spent organic Li-ion battery, ChemSusChem, 2014.
Contacts:
Accociate Professor Daniel Brandell, tel. +46-(0)73-943 59 32 or daniel.brandell@kemi.uu.se.
Stéven Renault, tel. +46-(0)18-471 37 76 or steven.renault@kemi.uu.se.
Smart, eco-friendly new battery to solve problems
2014-09-29
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
Protein that causes frontotemporal dementia also implicated in Alzheimer's disease
2014-09-29
SAN FRANCISCO, CA—September 28, 2014—Researchers at the Gladstone Institutes have shown that low levels of the protein progranulin in the brain can increase the formation of amyloid-beta plaques (a hallmark of Alzheimer's disease), cause neuroinflammation, and worsen memory deficits in a mouse model of this condition. Conversely, by using a gene therapy approach to elevate progranulin levels, scientists were able to prevent these abnormalities and block cell death in this model.
Progranulin deficiency is known to cause another neurodegenerative disorder, frontotemporal ...
Predicting landslides with light
2014-09-29
WASHINGTON, Sept. 29, 2014—Optical fiber sensors are used around the world to monitor the condition of difficult-to-access segments of infrastructure—such as the underbellies of bridges, the exterior walls of tunnels, the feet of dams, long pipelines and railways in remote rural areas.
Now, a team of researchers in Italy are expanding the reach of optical fiber sensors "to the hills" by embedding them in shallow trenches within slopes to detect and monitor both large landslides and slow slope movements. The team will present their research at The Optical Society's (OSA) ...
Scientists identify the signature of aging in the brain
2014-09-29
How the brain ages is still largely an open question – in part because this organ is mostly insulated from direct contact with other systems in the body, including the blood and immune systems. In research that was recently published in Science, Weizmann Institute researchers Prof. Michal Schwartz of the Neurobiology Department and Dr. Ido Amit of Immunology Department found evidence of a unique "signature" that may be the "missing link" between cognitive decline and aging. The scientists believe that this discovery may lead, in the future, to treatments that can slow or ...
Nivolumab shows signs of superior response rate compared to standard chemo in advanced melanoma
2014-09-29
The monoclonal antibody nivolumab achieves superior response rates and a longer duration of response than standard chemotherapy[1] in patients whose melanoma has progressed after treatment with ipilimumab, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
"Previously-treated advanced melanoma patients have limited options," says the study's principal investigator, Professor Jeffrey Weber, Director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at the Moffitt Cancer Centre, Tampa, Florida.
Nivolumab is an antibody ...
New data on combination treatments for melanoma
2014-09-29
Combination therapy with both BRAF inhibitor vemurafenib and MEK inhibitor cobimetinib achieves greater progression-free survival and response rates than vemurafenib plus placebo in BRAF-mutation positive melanoma, according to phase III data presented at the ESMO 2014 Congress in Madrid, Spain.
"Before the results of this study, we knew that cobimetinib plus vemurafenib could be safely delivered together with highly promising rates of tumour shrinkage; however until the performance of a scientifically rigorous randomised trial the potential magnitude of this benefit ...
Studies report new findings on treatment options for mesothelioma
2014-09-29
Treating patients with high-dose radiotherapy after chemotherapy and surgery for malignant pleural mesothelioma does not achieve improvements in local relapse and overall survival, according to data from a prospective randomized phase II trial presented at ESMO 2014 Congress in Madrid.
"Mesothelioma remains a difficult disease to find better treatment options for, so we asked whether high-dose hemithoracic radiotherapy would decrease the rate or delay the time of local recurrence after chemotherapy and radical surgery," says lead author Prof Rolf A. Stahel, from the ...
Promising results shown with targeted approaches in subsets of non-small cell lung cancer
2014-09-29
The BRAF inhibitor dabrafenib has significant anti-tumour activity in patients with advanced BRAF V600E mutant non-small cell lung cancer whose disease has progressed after chemotherapy, according to phase II data presented at the ESMO 2014 Congress in Madrid, Spain.
"Reports of lung cancers bearing mutations in BRAF have generated considerable interest because these mutations may be associated with increased sensitivity to BRAF tyrosine-kinase inhibiting agents," says lead author Dr David Planchard, pulmonary oncologist at the Gustav-Roussy Cancer Campus, Paris, France. ...
Scientists make droplets move on their own
2014-09-29
Droplets are simple spheres of fluid, not normally considered capable of doing anything on their own. But now researchers have made droplets of alcohol move through water. In the future, such moving droplets may deliver medicines, etc.
To be able to move on your own – to be self-moving – is a feature normally seen in living organisms. But also non-living entities can be self-moving, report researchers from University of Southern Denmark and Institute of Chemical Technology in Prague, Czech Republic.
The researchers have made alcohol droplets move in a life-like way, ...
Avoid skunky beer this Oktoberfest with the help of chemistry
2014-09-29
WASHINGTON, Sept. 29, 2014 — Oktoberfest is here, and that means beer. And there's nothing worse than reaching for a cold one, taking that first sip and realizing your beer's been skunked: chemicals have reacted to form compounds that cause an awful, bitter taste. This week, Reactions explains why beers get skunky, and what you can do to keep your brews from going bad. Learn all about it at http://youtu.be/9i4dHdQzTFg.
INFORMATION:
Subscribe to the series at Reactions YouTube, and follow us on Twitter @ACSreactions to be the first to see our latest videos.
The American ...
Ancient human genome from southern Africa throws light on our origins
2014-09-29
What can DNA from the skeleton of a man who lived 2,330 years ago in the southernmost tip of Africa tell us about ourselves as humans? A great deal when his DNA profile is one of the 'earliest diverged' – oldest in genetic terms – found to-date in a region where modern humans are believed to have originated roughly 200,000 years ago.
The man's maternal DNA, or 'mitochondrial DNA', was sequenced to provide clues to early modern human prehistory and evolution. Mitochondrial DNA provided the first evidence that we all come from Africa, and helps us map a figurative genetic ...